公开(公告)号：US20220281977A1

公开(公告)日：2022-09-08

申请号：US17630426

申请日：2020-07-29

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Takuya SHIMBO ,  Tomoya TEZUKA ,  Mark THROSBY ,  Cornelis Adriaan DE KRUIF ,  Pieter Fokko VAN LOO ,  Rinse KLOOSTER

IPC: C07K16/28 ,  C07K16/46 ,  A61P37/02

Abstract: A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.

公开(公告)号：US20220185885A1

公开(公告)日：2022-06-16

申请号：US17601354

申请日：2020-04-03

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Tomoya TEZUKA ,  Mark THROSBY ,  Cornelis Adriaan DE KRUIF ,  Pieter Fokko VAN LOO ,  Rinse KLOOSTER ,  Robertus Cornelis ROOVERS

IPC: C07K16/28

Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.

公开(公告)号：US20220332825A1

公开(公告)日：2022-10-20

申请号：US17633092

申请日：2020-08-07

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Tomoya TEZUKA

IPC: C07K16/28 ,  A61P37/06

Abstract: A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.

公开(公告)号：US20210214441A1

公开(公告)日：2021-07-15

申请号：US16967668

申请日：2019-02-08

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Takuya SHIMBO ,  Tomoya TEZUKA ,  Mark THROSBY ,  Cornelis Adriaan de KRUIF ,  Pieter Fokko van LOO ,  Rinse KLOOSTER

IPC: C07K16/28 ,  A61P37/02 ,  C07K16/46 ,  A61K45/06 ,  A61K39/00

Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.

公开(公告)号：US20200317783A1

公开(公告)日：2020-10-08

申请号：US16753159

申请日：2018-10-05

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Tomoya TEZUKA

IPC: C07K16/28

Abstract: A prophylactic, symptom progress-suppressive, recurrence-suppressive and/or therapeutic agent for autoimmune disease or graft-versus-host disease, comprising a PD-1/CD19 bispecific antibody or antibody fragment thereof having a first arm capable of specifically binding to PD-1 and a second arm capable of specifically binding to CD19, as an active ingredient. The PD-1/CD19 bispecific antibody exhibits suppressive effect on proliferation of activated B cells and suppressive effect on production of immunoglobulin, and also has an effect of suppressing production of cytokine from memory T cells.